Pharmaceutical Companies in Sweden

Gesynta Pharma's drug candidate GS-248 is in clinical phase II development for the treatment of endometriosis – a painful, chronic inflammatory disease that affects about 10 percent of women of reproductive age. Endometriosis often leads to severely reduced quality of life and current drug treatments are inadequate for many patients. Gesynta Pharma aims to exploit the full potential of microsomal prostaglandin E synthase-1 (mPGES-1) as a pharmacological target by developing products in areas of unmet medical need where mPGES-1 inhibition provides clear benefits compared to current therapy. The company's next drug candidate, GS-073, is ready to enter clinical phase I in 2023. Gesynta Pharma bases its R&D on research from the Karolinska Institutet. Major shareholders include Industrifonden, Hadean Ventures, Linc, and a number of successful life science entrepreneurs.

ICONOVO AB is developing proprietary inhalation products for licensing. We have long experience and track record in the development of dry powder inhalers and offer a comprehensive range of devices to our clients. Our selection of device concepts for dry powder inhalation include a reservoir inhaler, a pre-metered inhaler, a capsule based inhaler and a single dose disposable inhaler. We can also provide formulation development, performance testing, documentation and a complete supply-chain.

Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of opioid dependence and chronic pain, rare diseases, oncology and supportive care, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX.

Trialbee is revolutionizing the patient recruitment ecosystem with technology, people, and passion. The company’s vendor-agnostic Honey Platform™ is a SaaS Patient Recruitment Platform that centralizes and standardizes all recruitment activities from every source, channel, and partner from interest through enrollment – providing unprecedented transparency and actionable insights for real-time patient tracking, higher-quality referrals that reduce site burden, and robust ROI reporting. Honey is surrounded by a team of Precision Recruitment experts who meet patients where they are in their journey with data-driven modeling based on consumer behavior and other real-world data, hyper-targeted digital outreach, two-step pre-qualification, and meaningful Omnichannel partners focused on patient advocacy, community engagement, and diversity. To take control of patient recruitment for your next study, visit http://www.trialbee.com/.

Ziccum's ambient drying technology LaminarPace opens up unique thermostable formulation possibilities for next-generation biomolecules - from vaccines to protein therapeutics.

Galenica is a Swedish privately owned pharmaceutical company, authorized and audited by the Swedish Medical Product Agency. Galenica was founded in 1999 and has grown to 80 employees with expertise and balance between academic knowledge and industrial experience. Galenica is located in Medeon Science Park with 4000 m² state-of-the-art facilities. Our activities are divided into two business units: Contract Development Manufacturing Organization (CDMO) and Development and launching of own branded pharmaceutical products (PHARMA). Within CDMO (Contract Development Manufacturing Organization), Galenica supports and guides our partners in their pharmaceutical development programs and manufactures commercially niched products for our customers to bring to the market. We have vast expertise in pharmaceutical and analytical development as well as in production of Clinical Trial Material (CTM) for Phase I up to Phase III of all common non-sterile dosage forms. The PHARMA unit actively develops and launches our own pharmaceutical products which has a focus on derma, utilizing our state-of-the-art expertise in drug formulation, manufacturing, and quality control. Galenica has a proven track record when it comes to quality, knowledge and flexibility as well as keeping timelines. We combine state-of-the-art equipment with strong personal commitment, far-reaching clinical experience with tough perseverance, expertise in drug formulation with a solution-oriented determination. Since the start, we have supported and guided hundreds of clients in their pharmaceutical development programs and launched several self-made products.

Egetis Therapeutics is a Swedish pharmaceutical company based in Stockholm, specializing in the late-stage development and commercialization of innovative treatments for serious rare diseases.

We focus on addressing significant unmet medical needs within the orphan drug segment, developing therapies like Emcitate® for MCT8 deficiency and Aladote® for paracetamol overdose.

Egetis distinguishes itself through its integrated approach to drug development, combining scientific expertise with a commitment to patient access. Our dedication to bringing life-changing medicines to patients with rare conditions drives our strategic focus and operational excellence.

Founded with a vision to transform patient outcomes, Egetis Therapeutics continues to expand its pipeline and global reach, solidifying its position as a key player in the pharmaceutical industry.

Sever Pharma Solutions brings your pharmaceutical ideas to life by offering expertise in high potent drug development, a drive to enhance performance, a passion for perfection, and a commitment to be your partner through the whole journey. We add value through the entire development and manufacturing processes with in-depth analytics, expertise in high potent drugs and polymer-based drug delivery systems, comprehensive material options, and creative solutions. By providing a complete value chain, from development to sourcing and worldwide commercial supply, we can offer you an optimized end-to-end solution. And as a committed long-term partner with a strong focus on creating a commercial product, we put all our resources at work for you to the finishing line – and beyond. Together with our global GMP compliance, regulatory services, and market access strategies, we can secure that your products will benefit patients all over the world.